Company intelligence / Profile preview

Gisikai

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Gisikai is a biotechnology company focused on developing novel small molecule therapeutics for neurodegenerative disorders, with a primary emphasis on Alzheimer's disease. The company's approach centers on identifying and modulating specific biological pathways that contribute to neuronal dysfunction and cognitive decline. Led by experienced industry veterans, Gisikai aims to deliver first-in-class oral treatments that address the root causes of neurodegeneration rather than just managing symptoms. The company is currently in the pre-clinical stage of development, advancing its lead programs toward regulatory filings.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Gisikai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gisikai.

Explore the full profile